The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. - sprookjes - yvandenbroek - TriplyDB

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

http://www.wikidata.org/entity/Q34276618

about

How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion Cancer pharmacogenomics: strategies and challenges Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review Comparison of delivery strategies for pharmacogenetic testing services Pharmacogenomics and cardiovascular disease Pharmacogenomics discovery and implementation in genome-wide association studies era Phenotype standardization for statin-induced myotoxicity Muscular effects of statins in the elderly female: a review Use of contemporary genetics in cardiovascular diagnosis Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis Overcoming Challenges With Statin Therapy Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing Pharmacogenomics of statins: understanding susceptibility to adverse effects Pharmacogenomics: personalizing pediatric heart transplantation A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin.Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.Candidate-Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol-Lowering Response to Simvastatin PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.Synergistic interaction between genetics and disease on pravastatin disposition Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program.Horizon scanning for translational genomic research beyond bench to bedside.Applied pharmacogenomics in cardiovascular medicine Clinical interpretation and implications of whole-genome sequencing.Implementation and utilization of genetic testing in personalized medicine.Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants Statins and breast cancer prognosis: evidence and opportunities.The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.Pharmacogenomics and individualized medicine: translating science into practice.Pharmacogenetics in clinical practice: how far have we come and where are we going?Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.Genomic prediction of complex human traits: relatedness, trait architecture and predictive meta-models.Mechanisms and assessment of statin-related muscular adverse effects.Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia.

P2860

Q24273350-FE1D5805-AFF8-4A1D-AD7F-13B6156F22FA Q24289309-820FC6D8-7A65-407C-BA32-F99949B5CE69 Q24567778-923391F8-58C5-466B-B154-B36B699F0881 Q24598793-12235E92-9E6B-464B-A6D0-A3E6D7A884E5 Q26823434-251E5D7E-D53F-44F2-B69A-9468E0488E19 Q26860925-A99CBBDF-B9F9-4E34-94B0-99B20F25FB76 Q26997380-643FBF20-4D34-4BD6-B56A-1091FF377159 Q27001573-90254658-27C6-4130-BF26-BD0933C85180 Q27020935-F9FF8BA7-5AAC-4C78-92FC-6B1059334EB9 Q27023343-D46BD8D1-4428-4A39-94B3-88795F88406C Q27025306-4B461AF8-46BA-49BD-AEA5-1CEECE54C086 Q28070052-AB0C0E7C-5BC4-43BA-A5E5-80EEF386FF45 Q28073319-D344DF6E-0BA7-4481-87FD-378B2A13A836 Q28079766-1D153FAC-3CDB-402B-8154-78E3CD4AD9DD Q28079822-9DAECF4E-7A37-41E3-968D-21A8FEEF5C30 Q28081200-6F24FD03-B429-43D5-A969-795AF71C6E31 Q28554199-0273DD02-06DB-4688-B10C-2D272D3BDF22 Q30490270-083CDF6F-8A46-47C8-8A45-C562FAAEB5AB Q30572528-5F0DB637-7614-490E-8027-BC9E3F772197 Q30612258-860844F4-3C15-4B2D-92F2-E81C0FDE81DD Q31058146-086A9537-1D5D-4390-889E-4510E50112C4 Q33648028-519BB5BD-1720-46C9-B1FE-0FB8111A6EAF Q33751939-2D940DDB-60D4-4E09-8FC9-075512519D46 Q33786577-CBA14B64-BC22-40C1-A8C4-FD269E63C915 Q33792154-8E5B690B-B88E-4F02-BC26-46BB0635785E Q33838486-18D563ED-A11B-41F4-A53F-B2FF28A4E441 Q33846255-9DBCF5D2-EDBF-466C-9541-E86BF1A00F05 Q33989890-3FFE5B53-FCAF-4769-9624-FDECFC3128F0 Q34147916-DC51B482-85D5-43C7-BF61-0EDB0785B4B2 Q34163351-745CBFD2-C832-4FE2-8F8C-6D6B4D81D8A8 Q34206487-517EF243-CA07-4D0F-8486-F1A7F1258F3C Q34216710-E2387EF0-648A-4048-81B8-6840ADC51BAC Q34297575-6BC37E33-E3D1-442E-9741-135756F4BAF8 Q34343365-D66713AA-3D7A-478F-A2B3-24B18CCCF50F Q34453666-721A683B-FACB-4707-A18C-68A9F8DB982A Q34473904-3B394B42-D317-44D0-8F14-6A3A6111677D Q34570995-706680A7-55F4-455F-A42E-CE25E00A2E9E Q34608646-F5F79CA5-0404-4244-AD52-157B1E1E5FB1 Q34680467-D02235F6-2052-4A8E-B0E2-625BD450FAAE Q34726677-D179121E-475D-4242-AC9F-A9763DB6675D

P2860

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

http://www.wikidata.org/entity/Q34276618

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The clinical pharmacogenomics ...... simvastatin-induced myopathy.

@ast

The clinical pharmacogenomics ...... simvastatin-induced myopathy.

@en

The clinical pharmacogenomics ...... simvastatin-induced myopathy.

@nl

type

label

The clinical pharmacogenomics ...... simvastatin-induced myopathy.

@ast

The clinical pharmacogenomics ...... simvastatin-induced myopathy.

@en

The clinical pharmacogenomics ...... simvastatin-induced myopathy.

@nl

prefLabel

The clinical pharmacogenomics ...... simvastatin-induced myopathy.

@ast

The clinical pharmacogenomics ...... simvastatin-induced myopathy.

@en

The clinical pharmacogenomics ...... simvastatin-induced myopathy.

@nl

P1433

Q34276618-ED08799B-576E-42AF-B90A-99402BE36964

P1476

Q34276618-C3C77E76-0154-4151-9F87-3E9CAB6AC7B3

P2093

Q34276618-479C7307-9CA2-4A7F-B6F6-922E263D7363

Q34276618-50A27203-3C5D-4F94-92C3-7F1A39B61AF4

Q34276618-52B0D168-1103-4730-91AC-F9E0756B4E07

Q34276618-544ED456-C09E-4BE4-87C1-302D22B2C083

Q34276618-5DD49DB5-CD05-40F1-9D32-2584C0492FC3

Q34276618-AC0FC4E3-9019-4D68-B3C9-E7056011116E

Q34276618-AF369ADE-7525-42DF-833E-66C21749EF49

Q34276618-BB469EB4-74A4-4476-90BC-CCF34B5F7398

Q34276618-BF37903D-860C-49D5-A616-D97583A48822

Q34276618-C303CF25-FFCB-417C-AC40-916F855493BF

P2860

Q34276618-00705C48-BD76-47E8-8E98-405445056C68

Q34276618-0389D0D8-F590-47C7-832A-61A382B6441A

Q34276618-046FD1E3-3AC1-4D27-910A-D66BA6A520E7

Q34276618-0EC64FE6-B529-4B31-B0FE-CDDA9A162ACF

Q34276618-0EFAADBE-6F95-48C9-BD68-E46C90238D3A

Q34276618-0F0714F1-F726-40FC-B6A1-6AF2B74F0031

Q34276618-0FAFFE50-92A4-458B-8BCE-E4C83824EE81

Q34276618-1E52BAFE-D142-4A14-8B7C-8C8212F04C04

Q34276618-1FB1A3A9-20BB-4619-A4B4-1E4135FE561E

Q34276618-1FD24533-9668-44D9-84D6-19587D99B8DE

P304

Q34276618-B3631E3E-E872-4DB2-8F1F-65258ED1BCAF

P31

Q34276618-28F5C74D-69A9-4082-801E-FE30A86D1D43

P356

Q34276618-0A004474-4883-41D1-8518-E2E437B0ACE8

P407

Q34276618-17D6BDC0-6D23-4523-90CF-1380EA355D93

P433

Q34276618-800EAB50-5D81-44B7-A0A8-9242484F4D0D

P478

Q34276618-4BC3A924-C33B-445B-9CF0-56986B2E2FF6

P50

Q34276618-930215E4-155C-4D33-A220-61984FD0DC6E

Q34276618-C75DA3EF-B1E7-4878-9BDF-3AC85F0E8AC4

Q34276618-CD1DAE2C-09BF-4B03-8F18-49AC0E4E3559

Q34276618-EB1BDFA2-07E3-48A2-9149-37383BA25857

P577

Q34276618-3F05494A-E904-4DA9-A94F-245666073F84

P5875

Q34276618-9313473E-7621-4D19-A9E9-5E8B1D250252

P698

Q34276618-CC26DD1F-DE6F-411F-89BC-289D6EA96402

P921

Q34276618-7FA1C371-6E7A-463A-A396-45EC0C8F0252

P932

Q34276618-B34929F1-D8DD-47A2-BDA2-5936C8EFAF86

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

The clinical pharmacogenomics ...... d simvastatin-induced myopathy

@en

P2093

Clinical Pharmacogenomics Implementation Consortium (CPIC)

http://www.w3.org/2001/XMLSchema#string

D M Roden

http://www.w3.org/2001/XMLSchema#string

H L McLeod

http://www.w3.org/2001/XMLSchema#string

L Gong

http://www.w3.org/2001/XMLSchema#string

Q Feng

http://www.w3.org/2001/XMLSchema#string

R A Wilke

http://www.w3.org/2001/XMLSchema#string

R M Cooper-Dehoff

http://www.w3.org/2001/XMLSchema#string

R M Krauss

http://www.w3.org/2001/XMLSchema#string

S G Johnson

http://www.w3.org/2001/XMLSchema#string

T E Klein

http://www.w3.org/2001/XMLSchema#string

P2860

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

SLCO1B1 variants and statin-induced myopathy--a genomewide study

Statin-induced myopathy: a review and update.

Statin-associated myopathy.

Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors.

Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia.

P304

112-117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2012.57

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225055969

http://www.w3.org/2001/XMLSchema#string

P698

22617227

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

P932

3384438

http://www.w3.org/2001/XMLSchema#string